# Neutral pH Reversed Phase LC-MS Methodology for the Recovery and Characterization of Highly Acidic Peptides of Enbrel

**Waters** 

THE SCIENCE OF WHAT'S POSSIBLE."

Samantha Ippoliti<sup>1</sup>, Dale Cooper-Shepherd<sup>2</sup>, Ying Qing Yu<sup>1</sup>, Weibin Chen<sup>1</sup>, James I. Langridge<sup>2</sup> <sup>1</sup>Waters Corporation, Milford, MA, USA; <sup>2</sup>Waters Corporation, Wilmslow, UK

# Introduction

### Challenge:

- Some acidic peptides such as phosphopeptides and highly sialylated glycopeptides experience significant or complete analyte loss in conventional reversed phase liquid chromatography (LC).
- Conventional RP-LC mobile phase conditions are acidic in nature, causing residual metal oxides on the surfaces in the LC flow path to have nonspecific chelation reactions with negatively charged species.

#### Solution:

 We employ a neutral pH RPLC-MS method with post-column addition of acid, which allows us to detect and characterize these previously "unrecoverable" O-glycopeptides in conventional RPLC-MS methods. Herein, we demonstrate recovery of Enbrel<sup>TM</sup> highly sialylated T20 peptide which has previously only been detected after sialic acids have been removed<sup>1</sup>.


# Experimental

- LC-MS System: ACQUITY<sup>™</sup> H-Class coupled to Xevo<sup>™</sup> G2-XS
- ACQUITY Premier CSH C18 130Å, 1.7μm, 2.1 x 100mm Column
- MPA: 10mM Ammonium Acetate, pH 7.5
- MPB: 100% Acetonitrile
- Column Temp: 65 °C
  Gradient: 1-45%B in 50 min
- Load: 1-2 μg NIST mAb or Enbrel tryptic digest
- Post-Column Infusion of Formic Acid from integrated MS fluidics (1:10 ratio to LC flow rate)

Enbrel is a trademark of Immunex Corporation. ACQUITY and Xevo are trademarks of Waters Technologies Corporation.

# Results

### **NIST mAb Tryptic Digest**



#### Neutral pH Mobile Phase




Figure 1. TICs for NIST mAb tryptic digest in acidic vs neutral pH mobile phase conditions. 94% sequence coverage is achieved in both—all peptides matched in acidic conditions are also detected in neutral pH.

## **Enbrel T20 Highly Sialylated O-glycopeptides**




Figure 2. Extracted ion chromatogram of high energy channel of Enbrel tryptic digest in acidic (top) vs neutral (bottom) pH conditions, extracting for m/z 292 & 274, common oxonium ions for glycans containing sialic acid. Sialic acid-containing O-glycopeptides of T20 are only detected in the neutral pH condition.

eptide #	Peptide	# HexNAc	# Hex 💍	#NeuAc 🔷	Observed m/z	Relative Abundand
T1	LPAQVAFTPYAPEPGSTCR	0	0	0	688.00 (3+)	91.8%
		1	1	1	906.75 (3+)	4.5%
		1	1	2	1003.78 (3+)	3.6%
T16-18	PGTETSDVVCKPCAPGTFS NTTSSTDICRPHQICNVVAIP GNASMDAVCTSTSPTR (De-N-glycosylated)	0	0	0	1203.14 (5+)	39.4
		1	1	0	1276.17 (5+)	1.5
		1	1	1	1334.39 (5+)	46.2
		1	1	2	1392.60 (5+)	12.9
T19	SMAPGAVHLPQPVSTR	2	2	2	987.44 (3+)	79.2%
		2	1	1	836.39 (3+)	7.6%
		2	2	1	890.42 (3+)	2.6%
		1	1	1	768.70 (3+)	8.5%
		2	1	0	739.36 (3+)	2.1%
T20	SQHTQPTPEPSTAPSTSFLL PMGPSPPAEGSTGDEPK	7	7	6	1613.65 (5+)	4.0%
			6	7	1639.47 (5+)	3.1%
			7	7	1671.87 (5+)	9.8%
			7	8	1730.09 (5+)	17.3%
			7	9	1788.31 (5+)	17.4%
			7	10	1846.53 (5+)	12.9%
			7	11	1904.75 (5+)	4.2%
			6	6	1581.03 (5+)	1.2%
			6	8	1697.69 (5+)	2.2%
			6	9	1755.91 (5+)	1.7%
		6	6	6	1540.43 (5+)	3.1%
			5	7	1566.25 (5+)	1.9%
			6	7	1598.65 (5+)	6.4%
			5	8	1624.46 (5+)	1.3%
			6	8	1656.86 (5+)	7.2%
			6	9	1715.08 (5+)	6.3%
T22-23	THTCPPCPAPELLGGPSVF LFPPKPK	0	0	0	711.873 (4+)	93.6%
		1	1	1	875.9321 (4+)	4.1%
		1	1	2	948.7058 (4+)	2.3%

Table 1. List of ALL O-glycopeptides in Enbrel tryptic digest using neutral pH reversed phase chromatography. The previously "unrecoverable" T20 peptide was found with 6-7 Core 1 occupied sites, with a total of 6-11 sialic acids among them.

## Conclusions

Neutral pH reversed phase methodology is successful in mitigating chelation effects and improve recovery of highly sialylated peptides of Enbrel, while maintaining expected sequence coverage for typical peptide mapping experiments. We are currently investigating alternative fragmentation techniques such as ECD for site localization of the O-glycans.